menu search

Acceptance of polyamine inhibitor car-t combination abstract for online publication

MINNEAPOLIS, Oct. 25, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical s...

October 25, 2023, 12:15 pm

panbela to host third quarter 2023 earnings conference call on november 9, 2023

MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical s...

October 24, 2023, 12:15 pm

panbela to host third quarter 2023 earnings conference call on november 9, 2023

MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical...

October 24, 2023, 8:15 am

panbela to present at h.c. wainwright 25th annual global investment conference

MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-s...

August 28, 2023, 8:15 am

panbela announces issuance of new patent in europe for claims of a novel process for the production of sbp-101

Patent developed in collaboration with Syngene International Ltd. MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) — ...

August 14, 2023, 12:15 pm

panbela therapeutics, inc. (pbla) q2 2023 earnings call transcript

panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET C...

August 10, 2023, 10:42 pm

panbela opens enrollment in uk and germany for aspire trial in pancreatic cancer, all countries/regions in the aspire trial are now open and actively enrolling

Interim Data Analysis anticipated in Early 2024 MINNEAPOLIS, July 24, 2023 (GLOBE NEWSWIRE) — panbela...

July 24, 2023, 12:15 pm

panbela announces issuance of new patent in australia patent is for claims of a novel process for the production of sbp-101

Patent developed in collaboration with Syngene International Ltd. MINNEAPOLIS, July 17, 2023 (GLOBE NEWSWIRE) — ...

July 15, 2023, 6:59 am

panbela (pbla) up 11% on update from pancreatic cancer study

panbela (PBLA) rises 11% on a positive recommendation from an independent board reviewing safety data f...

July 11, 2023, 2:02 pm

panbela announces poster presentation at the endocrine society meeting: polyamine inhibition and β-cell preservation in recent onset type 1 diabetes

MINNEAPOLIS, June 26, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical s...

June 26, 2023, 12:15 pm

panbela announces sponsored research agreement to evaluate polyamine metabolic inhibitor therapy in combination with car-t cell therapy

MINNEAPOLIS, June 13, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical ...

June 13, 2023, 12:15 pm

panbela announces poster presentation at immunology of diabetes society meeting: evaluating the potential of cpp-1x (eflornithine) in recent onset type 1 diabetes

MINNEAPOLIS, June 01, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical s...

June 1, 2023, 12:15 pm

panbela announces clinical trial with moffitt cancer center for phase i/ii program in stk11 mutant non-small cell lung cancer

MINNEAPOLIS, May 22, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical st...

May 22, 2023, 12:15 pm

panbela therapeutics, inc. (pbla) q1 2023 earnings call transcript

panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Compa...

May 7, 2023, 7:42 am

panbela provides business update and reports q1 2023 financial results

MINNEAPOLIS, May 04, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical st...

May 4, 2023, 8:10 pm

panbela to host first quarter 2023 earnings conference call on may 4, 2023

MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical ...

April 24, 2023, 8:15 am

panbela (pbla) enrolls first patient for type 1 diabetes drug

panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1...

April 13, 2023, 2:26 pm

panbela therapeutics, inc. (pbla) q4 2022 earnings call transcript

panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Co...

March 16, 2023, 7:49 pm

panbela announces pricing of approximately $15 million public offering

MINNEAPOLIS, Jan. 26, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc. (Nasdaq: PBLA), (“...

January 26, 2023, 1:41 pm

panbela therapeutics, inc. (pbla) q3 2022 earnings calltranscripts

panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET...

November 13, 2022, 7:41 pm


Search within

Pages Search Results: